Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metronidazole + rifampin
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two antibiotics - metronidazole (a nitroimidazole antibiotic effective against anaerobic bacteria and certain parasites) and rifampin (also called rifampicin) is a bactericidal antibiotic that inhibits bacterial RNA synthesis. This combination has shown synergistic effects in eliminating persistent bacterial populations, particularly dormant Mycobacterium tuberculosis, and has been studied for treatment of tuberculosis and as part of broader antibiotic regimens for hidradenitis suppurativa.
02
Targets
NeuraminidaserpoB (DNA-directed RNA polymerase subunit beta)RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on metronidazole + rifampin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metronidazole + rifampin.